These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34186531)

  • 1. Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Wilkinson ST; Rhee TG; Joormann J; Webler R; Ortiz Lopez M; Kitay B; Fasula M; Elder C; Fenton L; Sanacora G
    Psychother Psychosom; 2021; 90(5):318-327. PubMed ID: 34186531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.
    Wilkinson ST; Wright D; Fasula MK; Fenton L; Griepp M; Ostroff RB; Sanacora G
    Psychother Psychosom; 2017; 86(3):162-167. PubMed ID: 28490030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
    Bottemanne H; Morlaas O; Claret A; Sharot T; Fossati P; Schmidt L
    JAMA Psychiatry; 2022 Nov; 79(11):1124-1132. PubMed ID: 36169969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
    Costi S; Soleimani L; Glasgow A; Brallier J; Spivack J; Schwartz J; Levitch CF; Richards S; Hoch M; Stade EC; Welch A; Collins KA; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Neuropsychopharmacology; 2019 Sep; 44(10):1812-1819. PubMed ID: 30858518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.
    Mathew SJ; Wilkinson ST; Altinay M; Asghar-Ali A; Chang LC; Collins KA; Dale RM; Hu B; Krishnan K; Kellner CH; Malone DA; Murrough JW; Ostroff RB; Sanacora G; Shao M; Anand A
    Contemp Clin Trials; 2019 Feb; 77():19-26. PubMed ID: 30572160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
    Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
    Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.
    Phillips JL; Van Geel A; Burhunduli P; Vasudev D; Batten LA; Norris S; Talbot J; Ortiz A; Owoeye O; Blier P
    Int J Neuropsychopharmacol; 2022 Dec; 25(12):992-1002. PubMed ID: 35931041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
    Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
    J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.
    Jha MK; Wilkinson ST; Krishnan K; Collins KA; Sanacora G; Murrough J; Goes F; Altinay M; Aloysi A; Asghar-Ali A; Barnett B; Chang L; Costi S; Malone D; Nikayin S; Nissen SE; Ostroff R; Reti I; Wolski K; Wang D; Hu B; Mathew SJ; Anand A
    JAMA Netw Open; 2024 Jun; 7(6):e2417786. PubMed ID: 38916891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
    J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
    Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
    Mol Psychiatry; 2020 Jul; 25(7):1592-1603. PubMed ID: 30283029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
    d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
    J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.